PL2118099T3 - Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy - Google Patents

Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy

Info

Publication number
PL2118099T3
PL2118099T3 PL08708929T PL08708929T PL2118099T3 PL 2118099 T3 PL2118099 T3 PL 2118099T3 PL 08708929 T PL08708929 T PL 08708929T PL 08708929 T PL08708929 T PL 08708929T PL 2118099 T3 PL2118099 T3 PL 2118099T3
Authority
PL
Poland
Prior art keywords
synthesis
kinase inhibitors
aminothiazole compounds
aminothiazole
compounds
Prior art date
Application number
PL08708929T
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
François Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of PL2118099T3 publication Critical patent/PL2118099T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL08708929T 2007-02-13 2008-02-13 Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy PL2118099T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
EP08708929A EP2118099B1 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2118099T3 true PL2118099T3 (pl) 2011-12-30

Family

ID=39332208

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08708929T PL2118099T3 (pl) 2007-02-13 2008-02-13 Proces syntezy związków 2-aminotiazolu jako inhibitorów kinazy
PL11170200T PL2366703T3 (pl) 2007-02-13 2008-02-13 Postać polimorficzna pochodnej 2-amino-(nitroarylo)-tiazolu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL11170200T PL2366703T3 (pl) 2007-02-13 2008-02-13 Postać polimorficzna pochodnej 2-amino-(nitroarylo)-tiazolu

Country Status (23)

Country Link
US (3) US8153792B2 (pl)
EP (2) EP2118099B1 (pl)
JP (2) JP5568312B2 (pl)
KR (1) KR20090110851A (pl)
CN (2) CN101657446B (pl)
AR (1) AR065337A1 (pl)
AT (1) ATE515506T1 (pl)
AU (1) AU2008214679A1 (pl)
BR (1) BRPI0807626B1 (pl)
CA (2) CA2677586C (pl)
ES (2) ES2369617T3 (pl)
HR (2) HRP20110709T1 (pl)
IL (1) IL200320A0 (pl)
MA (1) MA31180B1 (pl)
MX (1) MX2009008665A (pl)
NZ (1) NZ578944A (pl)
PL (2) PL2118099T3 (pl)
RU (2) RU2456285C2 (pl)
SI (2) SI2366703T1 (pl)
TN (1) TN2009000342A1 (pl)
TW (1) TWI406862B (pl)
WO (1) WO2008098949A2 (pl)
ZA (1) ZA200905981B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1525200B1 (en) 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US20120302577A1 (en) 2010-01-28 2012-11-29 Ab Science Treatment of gist with masitinib
TW201130830A (en) 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
AR081772A1 (es) 2010-06-02 2012-10-17 Ab Science Tratamiento de la artritis reumatoide con masitinib
US20140147415A1 (en) 2010-11-05 2014-05-29 Ab Science Treatment of mastocytosis with masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
WO2012136732A1 (en) 2011-04-08 2012-10-11 Ab Science Treatment of multiple myeloma with masitinib
ES2656640T3 (es) 2012-10-04 2018-02-27 Ab Science Uso de masitinib en combinación con gemcitabina para tratamiento de un subgrupo de pacientes que sufren de cáncer pancreático
TW201605449A (zh) 2013-12-02 2016-02-16 Ａｂ化學公司 馬賽替尼治療結腸直腸癌的用途
EP2886543A1 (en) 2013-12-18 2015-06-24 Sandoz Ag Crystalline form of mastinib mesylate
US20170196853A1 (en) 2014-06-02 2017-07-13 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
CN106794179A (zh) * 2015-07-29 2017-05-31 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
WO2017060308A1 (en) 2015-10-05 2017-04-13 Ab Science Treatment of severe systemic mastocytosis with masitinib
PT3240538T (pt) 2016-03-25 2021-12-07 Ab Science Uso de masitinib para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
WO2018177854A1 (en) 2017-03-31 2018-10-04 Sandoz Ag Crystalline form of masitinib
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
US20230000838A1 (en) 2019-11-22 2023-01-05 Ab Science Masitinib for the treatment of sickle cell disease
EP3831384A1 (en) 2019-12-02 2021-06-09 AB Science Use of masitinib for the treatment of eosinophilic asthma
AU2021223710A1 (en) 2020-02-20 2022-07-28 Ab Science Masitinib for the treatment of a multiple sclerosis patient subpopulation
CA3174748A1 (en) 2020-04-10 2021-10-14 Alain Moussy Use of masitinib for the treatment of coronavirus disease 2019 (covid-19)
KR20230125804A (ko) 2020-12-16 2023-08-29 에이비 사이언스 알츠하이머병의 치료를 위한 마시티닙
BR112023023934A2 (pt) 2021-05-17 2024-01-30 Ab Science Masitinibe para o tratamento de câncer de próstata resistente a castração
CN115850258A (zh) * 2022-12-27 2023-03-28 东北林业大学 一种马赛替尼的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
BR9809451A (pt) * 1997-05-22 2000-06-20 Searle & Co Pirazóis substituìdos com 3(5)-heteroarila como inibidores de quinase p38.
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
DE69835241T2 (de) * 1997-10-27 2007-05-31 Agouron Pharmaceuticals, Inc., La Jolla 4-Aminothiazol Derivate, deren Herstellung und deren Verwendung als Inhibitoren Cyclin-abhängiger Kinasen
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
KR20020027635A (ko) * 1999-09-10 2002-04-13 폴락 돈나 엘. 티로신 키나제 억제제
DE60223063T2 (de) 2001-06-29 2008-07-17 Ab Science C-kit inhibitoren
US20040266771A1 (en) 2001-06-29 2004-12-30 Alain Moussy Use of tyrosine kinase inhibitors for treating bone loss
ATE401079T1 (de) 2001-06-29 2008-08-15 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
WO2003004006A2 (en) 2001-06-29 2003-01-16 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
ES2274075T3 (es) 2001-06-29 2007-05-16 Ab Science Utilizacion de inhibidores de c-kit para tratar enfermedades inflamatorias intestinales (eii).
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
EP1401413B1 (en) 2001-06-29 2006-11-22 AB Science Use of tyrosine kinase inhibitions for treating allergic diseases
WO2003002114A2 (en) 2001-06-29 2003-01-09 Ab Science Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis
WO2003002107A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
ES2266553T3 (es) 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
US20040242612A1 (en) 2001-09-20 2004-12-02 Alain Moussy Use of tyrosine kinase inhibitors for promoting hair growth
WO2003039550A1 (en) 2001-09-20 2003-05-15 Ab Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
WO2003035049A2 (en) 2001-09-20 2003-05-01 Ab Science Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections
WO2003072090A2 (en) 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating cns disorders
EP1490067B1 (en) 2002-02-27 2008-09-17 AB Science Use of tyrosine kinase inhibitors for treating substance use disorders
PL373842A1 (pl) * 2002-05-29 2005-09-19 Amgen Inc. Pochodne 2-okso-1,3,4-trihydrochinazolinylowe przeznaczone do leczenia chorób związanych z proliferacją komórek
EP1525200B1 (en) * 2002-08-02 2007-10-10 AB Science 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
WO2004072068A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US20080025916A1 (en) 2003-02-27 2008-01-31 Ab Science Tailored Treatment Suitable for Different Forms of Mastocytosis
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
CA2533774A1 (en) * 2003-07-29 2005-02-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005016323A2 (en) 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
KR100848067B1 (ko) * 2003-12-25 2008-07-23 니뽄 신야쿠 가부시키가이샤 아미드 유도체 및 의약
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
CN101657446B (zh) 2013-05-15
PL2366703T3 (pl) 2015-02-27
EP2118099A2 (en) 2009-11-18
US8940894B2 (en) 2015-01-27
SI2118099T1 (sl) 2011-11-30
CA2970628A1 (en) 2008-08-21
TWI406862B (zh) 2013-09-01
US20120196871A1 (en) 2012-08-02
JP2010518141A (ja) 2010-05-27
EP2118099B1 (en) 2011-07-06
HRP20110709T1 (hr) 2011-11-30
ZA200905981B (en) 2010-11-24
CN103342701B (zh) 2016-09-21
EP2366703B1 (en) 2014-07-30
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
JP2013177437A (ja) 2013-09-09
JP5784073B2 (ja) 2015-09-24
TW200848419A (en) 2008-12-16
US20130289045A1 (en) 2013-10-31
AU2008214679A1 (en) 2008-08-21
WO2008098949A3 (en) 2008-10-02
US8153792B2 (en) 2012-04-10
EP2366703A1 (en) 2011-09-21
KR20090110851A (ko) 2009-10-22
ES2369617T3 (es) 2011-12-02
CN101657446A (zh) 2010-02-24
BRPI0807626A2 (pt) 2014-11-25
SI2366703T1 (sl) 2014-10-30
CA2677586C (en) 2017-07-25
RU2456285C2 (ru) 2012-07-20
CN103342701A (zh) 2013-10-09
TN2009000342A1 (en) 2010-12-31
AR065337A1 (es) 2009-06-03
ES2522169T3 (es) 2014-11-13
CA2970628C (en) 2019-08-27
US8492545B2 (en) 2013-07-23
IL200320A0 (en) 2010-04-29
BRPI0807626B1 (pt) 2022-03-03
RU2491286C1 (ru) 2013-08-27
JP5568312B2 (ja) 2014-08-06
CA2677586A1 (en) 2008-08-21
HRP20140986T1 (hr) 2014-11-21
MX2009008665A (es) 2009-08-21
NZ578944A (en) 2011-03-31
ATE515506T1 (de) 2011-07-15
WO2008098949A2 (en) 2008-08-21
RU2009132186A (ru) 2011-03-20

Similar Documents

Publication Publication Date Title
ZA200905981B (en) Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
HK1259148A1 (zh) 用作atr激酶抑制劑的化合物
HRP20170255T1 (hr) Postupak za pripremu spojeva korisnih kao inhibitori sglt-a
HK1144554A1 (en) Process for the preparation of compounds useful as inhibitors of sglt
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL206286A0 (en) Thiazole derivatives used as pi 3 kinase inhibitors
HK1161260A1 (zh) 用作 激酶抑制劑的化合物
PL2021335T3 (pl) Związki heterocykliczne jako inhibitory kinazy C-FMS
IL194356A0 (en) Novel cyclobutyl compounds as kinase inhibitors
ZA201000085B (en) 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors
HK1151291A1 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
ZA200903889B (en) Process for the synthesis of moxifloxacin hydrochloride
GB0702854D0 (en) Method for the synthesis of sucrose-6-esters
IL210573A0 (en) Compounds as kinase inhibitors
ZA201000482B (en) Process for the synthesis of e1 activating enzyme inhibitors
IL201245A0 (en) An improved process for the synthesis of solifenacin
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
EP2291077A4 (en) METHOD OF MANUFACTURING RHO-KINASE INHIBITOR COMPOUNDS
GB2459413B (en) Methods for the synthesis of perfluoroparacyclophane
EP2170902A4 (en) IMPROVED METHOD FOR SYNTHESIS OF OLANZAPINE
ZA200802990B (en) Process for the synthesis of compounds for selectin inhibition